Brief: Can Fite Biopharma Ltd Says Namodenoson's Treatment Of Liver Fibrosis Receives Notice Of Allowance From U.S. Patent Office
14/03/2022 11:25
March 14 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN FITE BIOPHARMA LTD - NAMODENOSON’S TREATMENT OF LIVER
FIBROSIS RECEIVES NOTICE OF ALLOWANCE FROM U.S. PATENT OFFICE
* CAN FITE BIOPHARMA LTD - BROAD PATENT ADDRESSES MARKETS
FOR THE
TREATMENT OF ALL ADVANCED LIVER FIBROSIS INDICATIONS
Further company coverage: CANF.TA
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage